Inhalable liposomal formulation for vasoactive intestinal peptide

International Journal of Pharmaceutics

Volumn 357, Issue 1-2, 2008, Pages 286-294

  Hajos, Franz ^a   Stark, Brigitte ^b   Hensler, Sigrid ^a   Prassl, Ruth ^b   Mosgoeller, Wilhelm ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

Drug inhalation; Liposome; Nanomedicine; VIP inhalation

Indexed keywords

LIPOSOME; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL TISSUE; ARTICLE; BRONCHIOLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; MALE; NEBULIZATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; TARGET ORGAN; VASODILATATION;

ADMINISTRATION, INHALATION; ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STORAGE; GASTROINTESTINAL AGENTS; INDICATORS AND REAGENTS; LIPOSOMES; MALE; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 42749089385     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.01.046     Document Type: Article

References (40)

1. Agu R.U., Ugwoke M.I., Armand M., Kinget R., and Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2 (2001) 198-209
2. Allen T.M. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 56 (1998) 747-756
3. Allen T.M., and Cullis P.R. Drug delivery systems: entering the mainstream. Science 303 (2004) 1818-1822
4. Allen T.M., and Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim. Biophys. Acta 1068 (1991) 133-141
5. Anabousi S., Kleemann E., Bakowsky U., Kissel T., Schmehl T., Gessler T., Seeger W., Lehr C.M., and Ehrhardt C. Effect of PEGylation on the stability of liposomes during nebulisation and in lung surfactant. J. Nanosci. Nanotechnol. 6 (2006) 3010-3016
6. Boissard C., Marie J.C., Hejblum G., Gespach C., and Rosselin G. Vasoactive intestinal peptide receptor regulation and reversible desensitization in human colonic carcinoma cells in culture. Cancer Res. 46 (1986) 4406-4413
7. Cryan S.A. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J. 7 (2005) 20-41
8. Delgado M., Munoz-Elias E.J., Gomariz R.P., and Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J. Immunol. 162 (1999) 1707-1716
9. Desai T.R., Hancock R.E., and Finlay W.H. A facile method of delivery of liposomes by nebulization. J. Control. Rel. 84 (2002) 69-78
10. Elhissi A.M., Faizi M., Naji W.F., Gill H.S., and Taylor K.M. Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures. Int. J. Pharm. 334 (2007) 62-70
11. Gololobov G., Noda Y., Sherman S., Rubinstein I., Baranowska-Kortylewicz J., and Paul S. Stabilization of vasoactive intestinal peptide by lipids. J. Pharmacol. Exp. Ther. 285 (1998) 753-758
12. Groneberg D.A., Hartmann P., Dinh Q.T., and Fischer A. Expression and distribution of vasoactive intestinal polypeptide receptor VPAC(2) mRNA in human airways. Lab. Invest. 81 (2001) 749-755
13. Groneberg D.A., Rabe K.F., and Fischer A. Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors. Eur. J. Pharmacol. 533 (2006) 182-194
14. Groneberg D.A., Springer J., and Fischer A. Vasoactive intestinal polypeptide as mediator of asthma. Pulm. Pharmacol. Ther. 14 (2001) 391-401
15. Hachisu M., Hiranuma T., Tani S., and Iizuka T. Enzymatic degradation of helodermin and vasoactive intestinal polypeptide. J. Pharmacobiodyn. 14 (1991) 126-131
16. Hamasaki Y., Mojarad M., and Said S.I. Relaxant action of VIP on cat pulmonary artery: comparison with acetylcholine, isoproterenol, and PGE1. J. Appl. Physiol. 54 (1983) 1607-1611
17. Izzo R.S., Scipione R.A., Pellecchia C., and Lokchander R.S. Binding and internalization of VIP in rat intestinal epithelial cells. Regul. Pept. 33 (1991) 21-30
18. Labiris N.R., and Dolovich M.B. Pulmonary drug delivery. Part II. The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56 (2003) 600-612
19. Lasic D.D. Novel applications of liposomes. Trends Biotechnol. 16 (1998) 307-321
20. Lian T., and Ho R.J. Trends and developments in liposome drug delivery systems. J. Pharm. Sci. 90 (2001) 667-680
21. Lilly C.M., Drazen J.M., and Shore S.A. Peptidase modulation of airway effects of neuropeptides. Proc. Soc. Exp. Biol. Med. 203 (1993) 388-404
22. Niven R.W. Delivery of biotherapeutics by inhalation aerosol. Crit. Rev. Ther. Drug Carrier. Syst. 12 (1995) 151-231
23. Niven R.W., Carvajal T.M., and Schreier H. Nebulization of liposomes. III. The effects of operating conditions and local environment. Pharm. Res. 9 (1992) 515-520
24. Niven R.W., and Schreier H. Nebulization of liposomes. I. Effects of lipid composition. Pharm. Res. 7 (1990) 1127-1133
25. Niven R.W., Speer M., and Schreier H. Nebulization of liposomes. II. The effects of size and modeling of solute release profiles. Pharm. Res. 8 (1991) 217-221
26. Önyüksel H., Sejourne F., Suzuki H., and Rubinstein I. Human VIP-alpha: a long-acting, biocompatible and biodegradable peptide nanomedicine for essential hypertension. Peptides 27 (2006) 2271-2275
27. Petkov V., Gentscheva T., Schamberger C., Haberl I., Artl A., Andreae F., and Mosgoeller W. The vasoactive intestinal peptide receptor turnover in pulmonary arteries indicates an important role for VIP in the rat lung circulation. Ann. NY Acad. Sci. 1070 (2006) 481-483
28. Petkov V., Mosgoeller W., Ziesche R., Raderer M., Stiebellehner L., Vonbank K., Funk G.C., Hamilton G., Novotny C., Burian B., and Block L.H. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J. Clin. Invest. 111 (2003) 1339-1346
29. Rubinstein I. Human VIP-alpha: an emerging biologic response modifier to treat primary pulmonary hypertension. Expert Rev. Cardiovasc. Ther. 3 (2005) 565-569
30. Saga T., and Said S.I. Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma. Trans. Assoc. Am. Physicians 97 (1984) 304-310
31. Said S.I. Vasoactive intestinal polypeptide (VIP) in asthma. Ann. NY Acad. Sci. 629 (1991) 305-318
32. Said S.I., and Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 169 (1970) 1217-1218
33. Sethi V., Onyuksel H., and Rubinstein I. Liposomal vasoactive intestinal peptide. Methods Enzymol. 391 (2005) 377-395
34. Shahbazian A., Baykuscheva-Gentcheva T., Petkov V., Hoeger H., Painsipp E., Holzer P., and Mosgoeller W. Involvement of endothelial NO in the dilator effect of VIP on rat isolated pulmonary artery. Regul. Peptides 139 (2007) 102-108
35. Stark B., Andreae F., Debbage P., Mosgoeller W., and Prassl R. Association of vasoactive intestinal peptide with polymer-grafted liposomes: structural aspects for pulmonary delivery. Biochim. Biophys. Acta 1768 (2007) 705-714
36. Tam E.K., and Caughey G.H. Degradation of airway neuropeptides by human lung tryptase. Am. J. Respir. Cell Mol. Biol. 3 (1990) 27-32
37. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4 (2005) 145-160
38. Waldrep J.C. New aerosol drug delivery systems for the treatment of immune-mediated pulmonary diseases. Drugs Today (Barc.) 34 (1998) 549-561
39. Waldrep J.C., Gilbert B.E., Knight C.M., Black M.B., Scherer P.W., Knight V., and Eschenbacher W. Pulmonary delivery of beclomethasone liposome aerosol in volunteers-tolerance and safety. Chest 111 (1997) 316-323
40. Waldrep J.C., Keyhani K., Black M., and Knight V. Operating characteristics of 18 different continuous-flow jet nebulizers with beclomethasone dipropionate liposome aerosol. Chest 105 (1994) 106-110